

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

Summary of Main Points from the Meeting held on Monday 14th December 2015

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the November 2015 meeting were approved and will be circulated.

3. Matters Arising

The Committee noted the matters arising from the previous meeting.

4. Formulary Applications

Full applications

- Nil

Individual funding requests (For noting)

- Nil

Ex-Panel Requests

- Esomeprazole 40mg injection

Decision: Accept

- Alogliptan 6.25mg tablets
Alogliptan 12.5mg tablets
Alogliptan 25mg tablets

Decision: Accept

Removals

- Nil

NWLIF

- North West London Red List

Medicines that hospital doctors should not ask GPs to prescribe.

Decision: Noted

- Biosimilar infliximab gainshare

Discussion on the biosimilar infliximab gainshare agreement.

Decision: Noted

5. Trust Medicines Policy

- Nil

6. Medicines Management

- Double checking of drugs in theatres

Decision: Defer to February meeting

The committee decided to defer this update from Dr Bernard Norman till the next committee meeting when the meeting is quorate.

- Ketamine Memo

Decision: Noted

Memo to highlight change in legislation with regards to ketamine schedule change.

- Withdrawal of BNF Memo

Decision: Noted

Memo, on behalf of the Patient Safety Group, to inform all clinical and administrative staff that the paper editions of the BNF and BNFC have been withdrawn due to a number of dosage errors and omissions.

- Influenza vaccine 2015/2016 Memo

Decision: Noted

Memo circulated to paediatric, pharmacy and nursing staff that the influenza vaccines 2015/2016 are now available. The memo also details dosing recommendations.

- Paediatric Antimicrobial Treatment Guidelines 2015-2016

Decision: Noted

Update to the paediatric antimicrobial treatment guidelines.

- Paediatric Surgical Prophylaxis Guidelines 2016

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

Decision: Noted

New guidance on paediatric surgical prophylaxis.

7. NICE TA Guidance

6 Technology Appraisals have been noted in November 2015

NICE TA Guidance November 2015

• **TA363 – Ledipasvir-sofosbuvir for treating chronic hepatitis C**

Ledipasvir-sofosbuvir (Harvoni) is recommended as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C

Action: Add to the formulary. Await short forms from hepatologists.

• **TA364 – Daclatasvir for treating chronic hepatitis C**

Daclatasvir (Daklinza) is recommended as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C, depending on their level of fibrosis. It is taken with sofosbuvir or peginteron alfa, and sometimes with a drug called ribavirin.

Action: Add to the formulary. Await short forms from hepatologists.

• **TA365 – Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C**

Ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) is recommended as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C. It is sometimes taken with ribavirin.

Action: Add to the formulary. Await short forms from hepatologists.

• **TA366 – Pembrolizumab for advanced melanoma not previously treated with ipilimumab**

Pembrolizumab (Keytruda) is recommended. This drug is a possible treatment for adults with melanoma that:

- can't be completely removed by surgery or has spread to other parts of the body
- has not been treated with ipilimumab before

Action: Already on the formulary. To update formulary for use in line with NICE TA366.

• **TA367 – Vortioxetine for treating major depressive episodes**

Vortioxetine is recommended as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode.

Action: Not applicable to C&W

• **TA368 – Apremilast for treating moderate to severe plaque psoriasis**

Apremilast is not recommended within its marketing authorisation for treating psoriasis, that is, for treating adults with moderate to severe chronic plaque psoriasis that has not responded to systemic therapy, or systemic therapy is contraindicated or not tolerated.

Action: Not recommended

NICE TA Short forms for Noting:

• **TA358 – Tolvaptan for treating autosomal dominant polycystic kidney disease**

Tolvaptan is recommended as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency only if:

- they have chronic kidney disease stage 2 or 3 at the start of treatment
- there is evidence of rapidly progressing disease and
- the company provides it with the discount agreed in the patient access scheme.

Action: For noting

• **TA359 – Idelalisib for treating chronic lymphocytic leukaemia**

Idelalisib, in combination with rituximab, is recommended:

- for untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation or
- for chronic lymphocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months.
- Idelalisib is recommended only if the company provides the drug with the discount agreed in the simple discount agreement.

Action: For noting

8. IVIG Update

Decision: Noted

• **IVIG requests**

Decision: Noted

November 2015

There were 12 IVIG issues in November 2015, with 5 new requests:

- One for ITP (Red indication)
- Two for Myasthenia Gravis (Blue indication)
- One for acquired cell plasia (Blue indication)
- One for inflammatory myopathies (Blue indication)

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

9. Items for noting

- **MHRA Update - November 2015**

Decision: Noted

MHRA update published November 2015.

- **Non-medical prescriber register – November 2015**

Decision: Noted

Trust non-medical prescriber register as of November 2015.

- **Non-Medical Prescriber Mandatory Training Update Day – Feedback**

Decision: Noted

Feedback from non-medical prescriber mandatory training update day held in November 2015.

- **Non-Medical Prescriber audit results**

Decision: Noted

Results from recently conducted non-medical prescriber audit results

- **Quarterly Controlled Drug Accountable Officer Report Q2 2015/2016**

Decision: Noted

Quarterly CD Accountable officer report Q2 2015/2016.

10. Meeting minutes for noting

- HIV Subcommittee Meeting
 - October 2015

Decision: Noted

Minutes from the HIV subcommittee meeting held in October 2015.

- Antimicrobial Steering Group Meeting
 - November 2015

Decision: Noted

Minutes from the Antimicrobial Steering Group meeting held in November 2015.

11. Joint Formulary

- **Joint formulary application form for NICE approved drugs**

Decision: Approved

A new joint formulary application form for NICE approved drugs to be used across both sites.

- **Advertisement for the role of a Chair for the Trust Medicines Group**

Decision: Noted

Advertisement for the role of a Chair for the new cross site Trust Medicines Group

13. Date of next meeting

Monday 8th February 2016: 8.00 - 9.00

Board Room: Lower Ground Floor, Lift Bank B

Closing date for papers: Friday 15th January 2016